BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 22727177)

  • 1. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
    Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
    Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
    Cunha-Vaz J; Ashton P; Iezzi R; Campochiaro P; Dugel PU; Holz FG; Weber M; Danis RP; Kuppermann BD; Bailey C; Billman K; Kapik B; Kane F; Green K;
    Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
    Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
    Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
    Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
    Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
    Campochiaro PA; Hafiz G; Shah SM; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane F;
    Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.
    Jain N; Stinnett SS; Jaffe GJ
    Ophthalmology; 2012 Jan; 119(1):132-7. PubMed ID: 21924503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
    Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
    Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
    Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
    Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema.
    Gillies MC; Simpson JM; Gaston C; Hunt G; Ali H; Zhu M; Sutter F
    Ophthalmology; 2009 Nov; 116(11):2182-7. PubMed ID: 19796823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.
    Callanan DG; Gupta S; Boyer DS; Ciulla TA; Singer MA; Kuppermann BD; Liu CC; Li XY; Hollander DA; Schiffman RM; Whitcup SM;
    Ophthalmology; 2013 Sep; 120(9):1843-51. PubMed ID: 23706947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
    Sutter FK; Simpson JM; Gillies MC
    Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
    Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
    Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema.
    Gibran SK; Khan K; Jungkim S; Cleary PE
    Ophthalmology; 2007 May; 114(5):890-4. PubMed ID: 17467527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal cortisone injection for refractory diffuse diabetic macular edema.
    Er H; Yilmaz H
    Ophthalmologica; 2005; 219(6):394-400. PubMed ID: 16286802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
    Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
    Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema.
    Sivaprasad S; Ockrim Z; Massaoutis P; Ikeji F; Hykin PG; Gregor ZJ
    Retina; 2008; 28(10):1435-42. PubMed ID: 18628722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
    Brown DM; Nguyen QD; Marcus DM; Boyer DS; Patel S; Feiner L; Schlottmann PG; Rundle AC; Zhang J; Rubio RG; Adamis AP; Ehrlich JS; Hopkins JJ;
    Ophthalmology; 2013 Oct; 120(10):2013-22. PubMed ID: 23706949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.